<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03232554</url>
  </required_header>
  <id_info>
    <org_study_id>IDA201706</org_study_id>
    <nct_id>NCT03232554</nct_id>
  </id_info>
  <brief_title>Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia</brief_title>
  <acronym>BXYMIDA</acronym>
  <official_title>Clinical Observation of The Gynecological Iron-Deficiency Anemia Treated With Buxue Yimu Pills</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates Buxue Yimu Pills，Ferrous Sulfate and the addition of Buxue Yimu Pills to
      Ferrous Sulfate in the treatment of Iron-Deficiency Anemia in adults women. One third of
      participanta will receive Buxue Yimu Pills, one third of participanta will receive Buxue Yimu
      Pills, one third of participanta will receive Ferrous Sulfate，and the another third will
      receive Buxue Yimu Pills and Ferrous Sulfate in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buxue Yimu Pills, Ferrous Sulfate each Improve anemia, but they do so by different
      machanisms. We generally treat patients with uncomplicated Iron Deficiency Anemia with oral
      iron due to the ease of administration，and Ferrous Sulfate is one of the most commonly used
      drugs.

      Buxue Yimu Pills consists of multiple chinses herbs including Angelica
      Sinensis，Astragalus，Donkey-Hide Gelatin，Herba Leonuri，Citrus etc., which gains widespread
      application in the treatment after women's abortion or operations of uterine cavity. Based on
      the characteristics above, we try to explore its clinical application value in Gynecological
      Iron-Deficiency Anemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Ferrous Sulfate，and the another third will receive Buxue Yimu Pills and Ferrous Sulfate in combination.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Blood Count</measure>
    <time_frame>5 minutes</time_frame>
    <description>Anemia Related Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Short Form-36 Health Survey (Sf-36)</measure>
    <time_frame>10 minutes</time_frame>
    <description>Information about health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose</measure>
    <time_frame>5 minutes</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Semiconductor Junction</measure>
    <time_frame>5 minutes</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram(ECG)</measure>
    <time_frame>5 minutes</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Metabolism index</measure>
    <time_frame>5 minutes</time_frame>
    <description>Anemia Related Assessment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabonomics Measurement</measure>
    <time_frame>1hour</time_frame>
    <description>Extensive and profound Information</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Iron-Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Buxue Yimu Pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buxue Yimu Pill 12g pill by mouth, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buxue Yimu Pills &amp;Ferrous Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous Sulfate 0.3g tablet by mouth, three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buxue Yimu Pills</intervention_name>
    <description>Buxue Yimu Pills 12g pill by mouth, twice daily.</description>
    <arm_group_label>Buxue Yimu Pills</arm_group_label>
    <other_name>Buxue Yimu pellets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buxue Yimu Pills &amp;Ferrous Sulfate</intervention_name>
    <description>Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily</description>
    <arm_group_label>Buxue Yimu Pills &amp;Ferrous Sulfate</arm_group_label>
    <other_name>Buxue Yimu pellets,Iron Sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>Ferrous Sulfate 0.3g tablet by mouth, three times daily</description>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
    <other_name>Iron Sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a female between the age of 18 and 50.

          -  Subject suffers from mild to moderate anemia with a hemoglobin between 80g/L and 110
             g/L.

          -  Subject has definite gynecological etiological factors of iron deficiency

          -  Subject provides written informed consent.

        Exclusion Criteria:

          -  Subject underwent chronic digestive tract inflammation，uncontrolled digestive or
             urinary system bleeding.

          -  Subject has other complications in addition to gynecological diseases leading to iron
             deficiency，such as hemorrhagic diseases of hematologic system，parasitic diseases like
             ancylostomiasis，chronic intravascular hemolysis，mechanical hemolysis like prosthetic
             valve，renal dysfunction and hemodialysis.

          -  Subject is pregnant or lactating.

          -  Subject has a severe systemic disease, such as cardiovascular system

          -  Subject has a history of malignancy or radiotherapy.

          -  Subject has undergone any Iron deficiency anemia treatment including Iron supplements
             or blood transfusion within 1month prior to randomization.

          -  Subject has mental disorder incapable of elementary cooperations.

          -  Subject has participated in other clinical researches of medicine within 1month prior
             to randomization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aijun AJ Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei L Li, MD</last_name>
    <phone>139-1198-8831</phone>
    <phone_ext>＋86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei L Li, MD</last_name>
      <phone>13911988831</phone>
      <phone_ext>＋86</phone_ext>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.journals.elsevier.com/best-practice-and-research-clinical-obstetrics-and-gynaecology</url>
    <description>Iron deficiency and iron deficiency anaemia in women</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406716/</url>
    <description>Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia.</description>
  </link>
  <results_reference>
    <citation>Percy L, Mansour D, Fraser I. Iron deficiency and iron deficiency anaemia in women. Best Pract Res Clin Obstet Gynaecol. 2017 Apr;40:55-67. doi: 10.1016/j.bpobgyn.2016.09.007. Epub 2016 Oct 1. Review.</citation>
    <PMID>28029503</PMID>
  </results_reference>
  <results_reference>
    <citation>Seid MH, Butcher AD, Chatwani A. Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia. 2017;2017:9642027. doi: 10.1155/2017/9642027. Epub 2017 Apr 13.</citation>
    <PMID>28487769</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Aijun Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Iron-Deficiency Anemia</keyword>
  <keyword>Buxue Yimu Pills</keyword>
  <keyword>Ferrous Sulfate</keyword>
  <keyword>clinical observations</keyword>
  <keyword>adult women</keyword>
  <keyword>Metabonomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Network platform, and the website will be attached later.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

